# Tempus AI: 3 Key Takeaways for Long-Term Investors

> Tempus AI's 2026 earnings show $193M data deals and $80M oncology pricing boost for long-term investors.
- Title: Tempus AI: 3 Key Takeaways for Long-Term Investors | Shortify
- Summary: Tempus AI's 2026 earnings show $193M data deals and $80M oncology pricing boost for long-term investors.
- Keywords: tempus ai, oncology, data licensing, average selling price, adjusted ebitda, diagnostic platform, The Motley Fool
- URL: https://shortify.news/The_Motley_Fool/tempus-ai-3-key-takeaways-for-long-term-investors
- Source: The Motley Fool — https://fool.com/earnings/takeaways/2026/11/19/tempus-ai-3-key-takeaways-for-long-term-investors
- Author: The Motley Fool Team
- Published: 2026-11-19T06:35:01+00:00
- Read time: 1 min
- Topics: tempus ai, oncology, data licensing, average selling price, adjusted ebitda, diagnostic platform, finance, money
## Q3 2026 Revenue
Tempus AI reported third-quarter 2026 revenue of $411.5 million, up 23% year over year.
## Multiyear Biopharma Deals
Long-term licensing agreements with biopharma partners like Pathos AI generate $193 million in data revenue over five years.

> Through this collaboration, Pathos is paying Tempus $55 million over a 5-year term. As a result, over the next approximately 5 years, we expect to generate $193 million of additional data and applications revenue from these agreements alone.
## Oncology Pricing Boost
FDA-approved pricing changes will add $80 million in oncology average selling price gains by 2027.

> Given the expansion of our FDA approval to include tumor-only for XT test, that updated pricing will kick in on January 1 and allow us to move the remaining XT over. That gives us about $80 million of uplift in oncology ASP in 2027.
## Positive Adjusted EBITDA
Tempus achieved positive adjusted EBITDA of $25.6 million in Q3 2026 after gross profit growth outpaced investments.
## Key takeaway

Tempus AI's third-quarter 2026 earnings report $411.5M revenue up 23% YoY with $193M data licensing and $80M oncology ASP gains expected by 2027.

---

Summary: Shortify — https://shortify.news/The_Motley_Fool/tempus-ai-3-key-takeaways-for-long-term-investors
Reporting: The Motley Fool — https://fool.com/earnings/takeaways/2026/11/19/tempus-ai-3-key-takeaways-for-long-term-investors

When you use this summary, link the Shortify URL for the summary and credit the reporting to its newsroom.